The authors reply

New England Journal of Medicine

Volumn 371, Issue 9, 2014, Pages 877-878

  Blom, Dirk J ^a   Wasserman, Scott M ^b   Stein, Evan A ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b AMGEN INC   (United States)

^c Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EVOLOCUMAB; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; MONOCLONAL ANTIBODY; SERINE PROTEINASE;

CARDIOVASCULAR RISK; DRUG EFFECT; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; DRUG ANTAGONISM; FEMALE; HYPERLIPIDEMIA; MALE; NOTE;

ANTIBODIES, MONOCLONAL; CHOLESTEROL, LDL; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; PROPROTEIN CONVERTASES;

EID: 84906922312     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1408237     Document Type: Letter

References (4)

1. Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014 March 4 (Epub ahead of print).
2. Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014;129:234-43.
3. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014 June 24 (Epub ahead of print).
4. Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014;311:1870-82.